Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Next Previous
Search
Trial Profile

A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RBX 2660 (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Acronyms PUNCHCD2
  • Sponsors Rebiotix

    • Most Recent Events

    • 06 Mar 2025 According to a Ferring Pharmaceuticals media release, Health Canada has issued a Notice of Compliance, approving REBYOTA (fecal microbiota, live), a novel first-in-class microbiome-restoration therapy indicated for the prevention of recurrence of Clostridioides difficile infection (C. diff) in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff based on results form PUNCH-CD clinical program including Phase 3 PUNCH CD3 trial.
    • 11 Jul 2023 According to a Ferring Pharmaceuticals media release, the integrated safety analysis of three phase 2 trials (PUNCH CD, PUNCH CD2, PUNCH Open-Label) and two phase 3(PUNCH CD3, PUNCH CD3-OLS) in Therapeutic Advances in Gastroenterology.
    • 11 Jul 2023 Results presented in the Ferring Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top